Discovering anticancer drug target combinations via network-informed signaling-based approach.

ABSTRACT:

Background

Oncologists deciding on cancer treatments must make difficult decisions as to which prescription and implementation strategies would best suit each patient. Much is still unknown about combinations of prescription drugs as there are many to choose from. At the outset, the oncologist reckons with at least two established facts: (i) patients receiving successive single molecules treatments are likely to experience drug resistance, and (ii), to select optimal drug combinations requires to pick the 'best' protein drug target combinations. Intuitively, target selection should precede drug selection, implying that well-informed strategies would opt to first consider drug targets - not drugs - combinations. Nowadays, drug combinations that oncologists consider are empirical and

SUBMITTER: Yavuz BR 

PROVIDER: S-EPMC12534536 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature